Table 1.
Study | Publication, year | Exposure status AFyes/AFno n/n | Endpoints considered | Cardiovascular diseases at baseline | Study design | Age, years, Mean | Men (%) | Follow-up, years Median | |
---|---|---|---|---|---|---|---|---|---|
Otterstad et al.27 | 2006 | 313/7352 | MI, HF, mortality | Yes | Cohort | Retrospective | 63.2 | 79 | 4.95 |
574/6778 | MI, HF, mortality | Yes | Subgroup | Retrospective | 63.3 | 79 | 4.95 | ||
Ruigomez et al.11 | 2008 | 831/8226 | CE,a HF | No | Cohort | Retrospective | 63.5 | 46.5 | 3.6 |
Goto et al.26 | 2008 | 713/10,850 | MI, HF, mortality | Yes | Cohort | Retrospective | 69.1 | 49.5 | 1 |
4725/32,999 | MI, HF, mortality | No | Subgroup | Retrospective | 68.3 | 69.9 | 1 | ||
Marte et al.11 | 2009 | 37/576 | Major CE,b mortality | Yes | Cohort | Prospective | 62.8 | 67.5 | 4.0 |
Bouzas-Mosquera et al.28 | 2010 | 619/16,481 | MI, mortality | Yes | Cohort | Retrospective | 64.3 | 59.1 | 6.5 |
Conen et al.24 | 2011 | 1011/33,711 | MI, mortality | No | Cohort | Prospective | 53 | 0 | 15.4 |
Jabre et al.25 | 2011 | 729/2187 | Mortality | Yes | Cohort | Prospective | 68 | 58 | 6.6 |
Bramlage et al.23 | 2013 | 455/5317 | Mortality | Yes | Cohort | Retrospective | 65.2 | 74.6 | 1 |
Soliman et al.22 | 2014 | 1631/22,297 | MI | No | Cohort | Prospective | 63.5 | 41.5 | 4.5 |
O’Neal et al.20 | 2014 | 434/4174 | MI | No | Cohort | Prospective | 72.5 | 40 | 12.2 |
Chao et al.21 | 2014 | 12,114/12,114 | MI | No | Cohort | Retrospective | 47.0 | 59.9 | 5.7 |
Andersson et al.29 | 2014 | 9519/12,468 | MI, mortality, HF | No | Cohort – women | Retrospective | 67.7 | 0 | 6.5 |
Cohort – men | Retrospective | 54.9 | 100 | ||||||
Rohla et al.19 | 2015 | 146/1288 | Mortality | Yes | Cohort | Prospective | 65.9 | 72.1 | 4.7 |
Soliman et al.5 | 2015 | 1545/12,917 | MI | No | Cohort | Prospective | 54 | 44 | 21.6 |
Vermond et al.13 | 2015 | 265/8000 | CV,c HF, mortality | No | Cohort | Prospective | 49 | 49.8 | 9.7 |
AF: atrial fibrillation; MI: myocardial infarction; HF: heart failure; CEs: cardiac events; CV: cardiovascular event.
CE defined as myocardial infarction, angina pectoris, percutaneous coronary intervention or coronary artery bypass grafting.
Major CE defined as coronary death and nonfatal myocardial infarction.
CV defined as cardiac events (acute myocardial infarction, acute and subacute ischaemic heart disease, coronary artery bypass grafting or percutaneous transluminal coronary angioplasty), cerebrovascular events (occlusion or stenosis of the precerebral or cerebral arteries or subarachnoid haemorrhage) and peripheral events (other vascular interventions such as percutaneous transluminal angioplasty or bypass grafting of the aorta and peripheral vessels).